Integrity in Science
Return to CSPI U.S.
SEARCH THE DATABASE of Scientists' and Non-Profits Ties to Industry

Lifting the Veil of Secrecy

WHO/International Agency for Research on Cancer

Press Releases

Resources

Conflicted Science: National Conference

CSPI's Funding Sources

Who We Are

Contact Us

 
(NOTE: Shortly after this letter was sent, and in response to it, Ms. Spayd reminded Washington Post reporters to inquire about conflicts of interest and to disclose them.)

Letter to Ms. Liz Spayd Concerning Articles With No Disclosure of Conflicts of Interest

March 23, 2001

Ms. Liz Spayd
National News Editor
Washington Post
1150 15th Street, N.W.
Washington, D.C. 20071-0070

Re: Articles with no disclosure of conflicts of interest

Dear Ms. Spayd:

I write to you concerning an article (“Study Tallies Americans’ Exposure to Toxins”) by David Brown, which appeared in yesterday’s Post. The article quotes David Ropeik of the Harvard Center for Risk Analysis (HCRA). In that article Mr. Ropeik downplays the findings of a recent study conducted by the Centers for Disease Control and Prevention — a study concerning possible health risks associated with 27 chemicals. What was not mentioned was the fact that Mr. Ropeik’s group has received funding from no fewer than 27 chemical companies/foundations, including Dow Chemical Company, Exxon Corporation, and the Chemical Manufacturing Association (now the American Chemistry Council). Accompanying this letter is the full list of the chemical funders of the HCRA.

The public is entitled to know about such conflicts in order to make more informed decisions about the reliability of the experts quoted. Otherwise, the impression is that such experts are “neutral” scientists with no vested interest in the matters upon which they offer opinions. My point is not that such financial ties categorically discredit or disqualify any expert, but rather that such information is useful to the public to consider. In that general regard, last year a study in the New England Journal of Medicine (vol. 342, #22) found that “News-media stories about medications may include inadequate or incomplete information about the benefits, risks, and costs of the drugs as well as the financial ties between the study groups or experts and pharmaceutical manufacturers.” (See abstract accompanying this letter.)

Last month I coauthored a letter (with Steven Gurney of NRDC) to the Post concerning a scientist quoted in a Post story about global warming. That story failed to mention that the scientist quoted had once served as a consultant to Exxon, Shell, ARCO, Ford and GM, among others. (A copy of that letter also accompanies this letter.) There are yet other such examples; I would be glad to provide them to you upon request.

As you well know, the problem of conflicts of interest in science is itself more and more in the news. Given that fact, the public interest would be well served by news reporters disclosing such facts about the sources they quote.

Accordingly, I respectfully urge the Post to encourage its reporters routinely to ask sources about possible conflicts of interest and to report that information to your readers.

Thank you for your consideration.

Sincerely Yours,
 

Ronald Collins
Integrity in Science Project
(202) 332-9110, #322
e-mail: ronc@cspinet.org

 

encls:

cc: Jackson Diehl, Howard Kurtz, Michael Getler, & David Brown.

 

Integrity in Science